Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective produ...
Product Name : Baxdela
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : Delafloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the license and distribution agreement, Helsinn Healthcare SA grants Xediton an exclusive license to distribute, promote, market, and sell TRUSELTIQ in Canada and Helsinn will supply TRUSELTIQ for commercialization in Canada.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 20, 2021
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $11.3 million
October 28, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Quantum Genomics
Deal Size : Undisclosed
Deal Type : Licensing Agreement